Clinical Trials Logo

Clinical Trial Summary

Familial amyloid neuropathy due to transthyretin gene mutations (TTR-FAP) is a rare autosomal dominant inherited disease resulting in the abnormal multi-system deposition of amyloid proteins. These deposits produce a multi-organ disease. AP is usually fatal 10 to 15 years after onset of symptoms if untreated. The prevalence of the disease remains still poorly understood and usually the search for this pathology is done in a third line of investigation. So the average time to diagnosis is extremely long, from 12 to 24 month. Now that the investigators have etiological treatment ( famidis (Vyndaqel®) and Diflunisal (Dolobid)) of this disease, it is essential to be able to detect FAP patients as early as possible. With this study, investigator decided to test for TTR mutation all patients presented with neuropathy of unknown etiology at the first line of investigation. The goal of this study is to evaluate the prevalence of FAP-TTR among neuropathy and defined the best strategy to test this population for TTR mutations.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03190577
Study type Interventional
Source Nantes University Hospital
Contact
Status Completed
Phase N/A
Start date September 21, 2017
Completion date May 23, 2022

See also
  Status Clinical Trial Phase
Completed NCT03588468 - Expanding the Biomarkers in Familial Amyloid Neuropathy: MRI and Motor Unit Estimation by Electrophysiological Study N/A
Completed NCT03591757 - Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR) Early Phase 1
Completed NCT05075798 - Study of Cerebral MRI Anomalies in Mutated Transthyretin Amyloidosis Patients
Recruiting NCT05577819 - Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF N/A
Terminated NCT04611204 - Transthyretin Cardiac Amyloidosis in Patients With Idiopathic Carpal Tunnel Syndrome Referred for Release Surgery
Completed NCT03352089 - Positron Emission Tomography / Magnetic Resonance Imaging in Aortic Stenosis
Recruiting NCT05814380 - The Regional Scintigraphic DPD Uptake in Cardiac Transthyretin Amyloidosis.
Completed NCT03923920 - Screening for Systemic Amyloidosis Via the Ligamentum Flavum
Completed NCT03886155 - Cardiac Amyloidosis Screening at Trigger Finger Release
Completed NCT03862807 - Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant Phase 3
Completed NCT02792790 - Carpal Tunnel Syndrome and Amyloid Cardiomyopathy
Completed NCT03860935 - Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy Phase 3
Not yet recruiting NCT06465810 - Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Recruiting NCT04963985 - The Effect of Tafamidis on Transthyretin Stabilization, Safety, Tolerability and Efficacy in Transthyretin Amyloid Polyneuropathy Patients Phase 4
Recruiting NCT05409833 - Systemic Transthyretin Amyloidosis: Carpal Tunnel Syndrome in a Portuguese Population
Recruiting NCT05635045 - Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR Phase 2
Completed NCT01171859 - Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin Amyloidosis Phase 2
Recruiting NCT03237494 - TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects
Recruiting NCT04899180 - Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis Early Phase 1
Recruiting NCT06345235 - New Biomarkers and Plasma Prothrombotic Potential in Cardiac Transthyretin Amyloidosis